Maurizio Scaltriti Human Oncology & Pathogenesis Program (HOPP) Memorial Sloan Kettering Cancer Center Biography Publications Institution JoVE Articles Maurizio Scaltriti has not added a biography. If you are Maurizio Scaltriti and would like to personalize this page please email our Author Liaison for assistance. Publications TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2019 | Pubmed ID: 31871300 Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer Cancer Discovery. Dec, 2019 | Pubmed ID: 31806627 Double Mutations in Cis Increase Oncogenicity and Sensitivity to PI3Kα Inhibitors Science (New York, N.Y.). 11, 2019 | Pubmed ID: 31699932 Resistance to TRK Inhibition Mediated by Convergent MAPK Pathway Activation Nature Medicine. 09, 2019 | Pubmed ID: 31406350 Cell-free DNA Analysis in Healthy Individuals by Next-generation Sequencing: a Proof of Concept and Technical Validation Study Cell Death & Disease. Jul, 2019 | Pubmed ID: 31296838 Solid Pseudopapillary Neoplasms of the Pancreas Are Dependent on the Wnt Pathway Molecular Oncology. 08, 2019 | Pubmed ID: 30972907 Prevalence and Role of HER2 Mutations in Cancer Pharmacology & Therapeutics. 07, 2019 | Pubmed ID: 30951733 PI3K Inhibition Activates SGK1 Via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression Cell Reports. 04, 2019 | Pubmed ID: 30943409 Author Correction: HER Kinase Inhibition in Patients with HER2- and HER3-mutant Cancers Nature. 02, 2019 | Pubmed ID: 30755741 MET Activation Confers Resistance to Cetuximab, and Prevents HER2 and HER3 Upregulation in Head and Neck Cancer International Journal of Cancer. 08, 2019 | Pubmed ID: 30694565 Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions Cancer Research. 03, 2019 | Pubmed ID: 30643016 and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer Cancer Discovery. 02, 2019 | Pubmed ID: 30463996 Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors Via the Hippo Pathway Cancer Cell. 12, 2018 | Pubmed ID: 30537512 NTRK Fusion-positive Cancers and TRK Inhibitor Therapy Nature Reviews. Clinical Oncology. 12, 2018 | Pubmed ID: 30333516 Neratinib is Effective in Breast Tumors Bearing Both Amplification and Mutation of ERBB2 (HER2) Science Signaling. 10, 2018 | Pubmed ID: 30301790 P95HER2-T Cell Bispecific Antibody for Breast Cancer Treatment Science Translational Medicine. 10, 2018 | Pubmed ID: 30282693 The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers Cancer Cell. 09, 2018 | Pubmed ID: 30205045 Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 08, 2018 | Pubmed ID: 29989854 Oncogenic TRK Fusions Are Amenable to Inhibition in Hematologic Malignancies The Journal of Clinical Investigation. 08, 2018 | Pubmed ID: 29920189 Coamplification of Protects -amplified Breast Cancers from Targeted Therapy Proceedings of the National Academy of Sciences of the United States of America. 03, 2018 | Pubmed ID: 29476008 HER Kinase Inhibition in Patients with HER2- and HER3-mutant Cancers Nature. 02, 2018 | Pubmed ID: 29420467 The Prognostic Value of PI3K Mutational Status in Breast Cancer: A Meta-analysis Journal of Cellular Biochemistry. 06, 2018 | Pubmed ID: 29345357 Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer Cancer Discovery. 01, 2018 | Pubmed ID: 29122777 A Network Modeling Approach to Elucidate Drug Resistance Mechanisms and Predict Combinatorial Drug Treatments in Breast Cancer Cancer Convergence. 2017 | Pubmed ID: 29623959 Genotyping Tumour DNA in Cerebrospinal Fluid and Plasma of a HER2-positive Breast Cancer Patient with Brain Metastases ESMO Open. 2017 | Pubmed ID: 29067216 Somatic Chromosomal Engineering Identifies BCAN-NTRK1 As a Potent Glioma Driver and Therapeutic Target Nature Communications. 07, 2017 | Pubmed ID: 28695888 A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors Cancer Discovery. 09, 2017 | Pubmed ID: 28578312 Overcoming Resistance to HER2-targeted Therapy with a Novel HER2/CD3 Bispecific Antibody Oncoimmunology. 2017 | Pubmed ID: 28405494 PI3K Pathway Regulates ER-dependent Transcription in Breast Cancer Through the Epigenetic Regulator KMT2D Science (New York, N.Y.). 03, 2017 | Pubmed ID: 28336670 Tumour-specific PI3K Inhibition Via Nanoparticle-targeted Delivery in Head and Neck Squamous Cell Carcinoma Nature Communications. 02, 2017 | Pubmed ID: 28194032 The Emerging Role of Serum/glucocorticoid-regulated Kinases in Cancer Cell Cycle (Georgetown, Tex.). 01, 2017 | Pubmed ID: 27636373 CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer Cell Reports. 11, 2016 | Pubmed ID: 27880910 PIM1 Kinase Regulates Cell Death, Tumor Growth and Chemotherapy Response in Triple-negative Breast Cancer Nature Medicine. 11, 2016 | Pubmed ID: 27775704 Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer Cancer Discovery. 10, 2016 | Pubmed ID: 27604488 Stratification and Therapeutic Potential of PML in Metastatic Breast Cancer Nature Communications. 08, 2016 | Pubmed ID: 27553708 PDK1-SGK1 Signaling Sustains AKT-Independent MTORC1 Activation and Confers Resistance to PI3Kα Inhibition Cancer Cell. 08, 2016 | Pubmed ID: 27451907 P-selectin is a Nanotherapeutic Delivery Target in the Tumor Microenvironment Science Translational Medicine. 06, 2016 | Pubmed ID: 27358497 Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 09, 2016 | Pubmed ID: 27081168 Somatic PIK3CA Mutations As a Driver of Sporadic Venous Malformations Science Translational Medicine. Mar, 2016 | Pubmed ID: 27030594 Pten Loss Promotes MAPK Pathway Dependency in HER2/neu Breast Carcinomas Proceedings of the National Academy of Sciences of the United States of America. Mar, 2016 | Pubmed ID: 26929372 Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2016 | Pubmed ID: 26763248 AKT Signaling in ERBB2-amplified Breast Cancer Pharmacology & Therapeutics. Feb, 2016 | Pubmed ID: 26645663 Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2016 | Pubmed ID: 26589432 High HER2 Protein Levels Correlate with Increased Survival in Breast Cancer Patients Treated with Anti-HER2 Therapy Molecular Oncology. Jan, 2016 | Pubmed ID: 26422389 MEK Plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2015 | Pubmed ID: 26272063 Quantification of HER Family Receptors in Breast Cancer Breast Cancer Research : BCR. Apr, 2015 | Pubmed ID: 25887735 PI3K Inhibition Results in Enhanced Estrogen Receptor Function and Dependence in Hormone Receptor-positive Breast Cancer Science Translational Medicine. Apr, 2015 | Pubmed ID: 25877889 AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas Cancer Cell. Apr, 2015 | Pubmed ID: 25873175 High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2015 | Pubmed ID: 25467182 Convergent Loss of PTEN Leads to Clinical Resistance to a PI(3)Kα Inhibitor Nature. Feb, 2015 | Pubmed ID: 25409150 Rationale-based Therapeutic Combinations with PI3K Inhibitors in Cancer Treatment Molecular & Cellular Oncology. Jul-Sep, 2014 | Pubmed ID: 27308344 Therapeutic Antibodies in Breast Cancer Seminars in Oncology. Oct, 2014 | Pubmed ID: 25440604 Effect of P95HER2/611CTF on the Response to Trastuzumab and Chemotherapy Journal of the National Cancer Institute. Nov, 2014 | Pubmed ID: 25253614 Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-negative Breast Cancer Science Signaling. Mar, 2014 | Pubmed ID: 24667376 Potential Biomarkers of Long-term Benefit from Single-agent Trastuzumab or Lapatinib in HER2-positive Metastatic Breast Cancer Molecular Oncology. Feb, 2014 | Pubmed ID: 24075779 Targeting the MUC1-C Oncoprotein Downregulates HER2 Activation and Abrogates Trastuzumab Resistance in Breast Cancer Cells Oncogene. Jun, 2014 | Pubmed ID: 23912457 Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068 Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2013 | Pubmed ID: 24141624 Clinical Response to a Lapatinib-based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation Cancer Discovery. Nov, 2013 | Pubmed ID: 23950206 MTORC1 Inhibition is Required for Sensitivity to PI3K P110α Inhibitors in PIK3CA-mutant Breast Cancer Science Translational Medicine. Jul, 2013 | Pubmed ID: 23903756 RSK3/4 Mediate Resistance to PI3K Pathway Inhibitors in Breast Cancer The Journal of Clinical Investigation. Jun, 2013 | Pubmed ID: 23635776 MTOR Kinase Inhibition Causes Feedback-dependent Biphasic Regulation of AKT Signaling Cancer Discovery. Aug, 2011 | Pubmed ID: 22140653 Cyclin E Amplification/overexpression is a Mechanism of Trastuzumab Resistance in HER2+ Breast Cancer Patients Proceedings of the National Academy of Sciences of the United States of America. Mar, 2011 | Pubmed ID: 21321214 AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity Cancer Cell. Jan, 2011 | Pubmed ID: 21215704 Clinical Benefit of Lapatinib-based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Tumors Coexpressing the Truncated P95HER2 Receptor Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2010 | Pubmed ID: 20406840 Inhibitors of HSP90 Block P95-HER2 Signaling in Trastuzumab-resistant Tumors and Suppress Their Growth Oncogene. Jan, 2010 | Pubmed ID: 19855434 In Vitro Estabelecimento de uma linha de células de câncer de urina de urina geneticamente modificada usando um sistema adeno associado de vírus-cas9 Manu Prasad*1,2, Sankar Jagadeeshan*1,2, Maurizio Scaltriti3, Irit Allon2,4, Moshe Elkabets1,2 1The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 2Faculty of Health Sciences, Ben-Gurion University of the Negev, 3Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 4Institute of Pathology, Barzilai University Medical Center JoVE 60410 Cancer Research
In Vitro Estabelecimento de uma linha de células de câncer de urina de urina geneticamente modificada usando um sistema adeno associado de vírus-cas9 Manu Prasad*1,2, Sankar Jagadeeshan*1,2, Maurizio Scaltriti3, Irit Allon2,4, Moshe Elkabets1,2 1The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev, 2Faculty of Health Sciences, Ben-Gurion University of the Negev, 3Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 4Institute of Pathology, Barzilai University Medical Center JoVE 60410 Cancer Research
